RE:In my opinion GBM trials should be fast tracked at I agree that GBM and NSCLC should be an immediate priority and every attempt should be made to fast track the clinical research. Indeed it is cruel to GBM and Lung Cancer patients when the cure is so close and existing knowledge and clinical suppors that the same success in complete and partial recovery rates can be safely achieved for these two types of cancers.
IMO, to reach the funding goals, TLT will have to work on Clinical Sites in the U.S first this time instead of keeping the U.S Clinical sites to the last phase, like it was done for NMIBC. For one thing, the data from a U.S study site is immediately validated and published. The FDA as well as the Industry in general (Major Pharma, Cancer care Hospitals, GP's and Surgical Oncologists who recommend treatment options to the patients, last but not least Banks and other financial institutions). I also believe the newly hired Director or Clinical Studies Dr. Madzarevic's knowledge and exposure to the Clinical research and the business side of the study (Novartis and President of Clinical Research institute of America) in the U.S would be invaluable to TLT.
So everything hinges on obtaining BTD as an immediate goal. Recognition for the PDT as a safe, quick and efficient way to find a cure or mitigate the damage caused by the Cancer Tumors and extend the quality of life. Obtaining financing at favourable terms for TLT of for that matter any company that has achieved BTD from FDA is a Given. I believe, RDW is Banking on achieving BTD before reaching out on Financing options for the immediate future. IMO, ,The delaying of financing options is clearly indicated in their decision to withdraw the Shelf offering that was in place with SEC, as well as their decision to allow the $ 0.35 warrant to expire in November. The stock price crossed the $ 0.35 barrier almost within weeks!!!